ArticleNature medicine2020

Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial.

Nirav N Shah et al.PubMed ↗Publisher ↗

No numbers read from the abstract.